Minirin/Ddavp (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney collecting ducts. This triggers a cascade that inserts aquaporin‑2 channels into the tubular membrane, allowing more water to be reabsorbed and concentrating urine. In endothelial cells, V2 activation releases factor VIII and von Willebrand factor, supporting haemostasis.

The appropriate dose of Minirin/Ddavp is individualized by the prescribing clinician based on the patient’s age, weight, renal function, severity of the condition, and response to therapy. No standard dosing regimen is provided here; the prescriber will set the exact amount and frequency.

Safety data for desmopressin acetate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Desmopressin acetate is a selective V2‑receptor agonist, offering a longer duration of action and fewer vasoconstrictive effects than natural vasopressin. Compared with other antidiuretic drugs, it provides more predictable water‑reabsorption and is the preferred choice for central diabetes insipidus and specific bleeding disorders because of its haemostatic benefits.

Store Minirin/Ddavp at ambient temperature, below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct sunlight, and avoid freezing. Ensure the container is tightly sealed when not in use.

Minirin/Ddavp is supplied as an injectable solution and may be given intramuscularly, intravenously, or subcutaneously by a qualified healthcare professional. The route, site and rate of injection are determined by the prescriber according to the indication and patient’s clinical status.

The most critical safety concerns include severe hyponatremia leading to neurological symptoms, water intoxication, seizures, and rare allergic reactions such as anaphylaxis. Patients should be monitored for sudden changes in mental status, excessive weight gain, or signs of fluid overload, and serum sodium should be checked regularly.

Minirin/Ddavp is contraindicated in patients with known hypersensitivity to desmopressin acetate, those with uncontrolled hyponatremia, and individuals with severe renal impairment where fluid balance cannot be safely managed. Caution is also advised for patients with a history of thromboembolic disease.